MarketPulse

IMCIVREE

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rhythm Pharmaceuticals, Inc.

Rhythm Pharma Wins FDA Nod for First-Ever Acquired Obesity Treatment

Rhythm Pharma wins FDA approval for IMCIVREE, the first therapy for acquired hypothalamic obesity, based on 18.4% placebo-adjusted BMI reduction.
RYTMFDA approvalrare disease
GlobeNewswire Inc.GlobeNewswire Inc.··Rhythm Pharmaceuticals, Inc.

Rhythm Pharma's Setmelanotide Shows 18.8% BMI Reduction in Obesity Trial

Rhythm Pharmaceuticals reports positive Phase 3 data for setmelanotide treating acquired hypothalamic obesity, with FDA decision expected March 2026.
RYTMFDA approvalrare disease